MPH Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medicure Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.00 |
| 52 Week High | CA$1.80 |
| 52 Week Low | CA$0.92 |
| Beta | 1.01 |
| 1 Month Change | -6.54% |
| 3 Month Change | -13.04% |
| 1 Year Change | -9.91% |
| 3 Year Change | -9.09% |
| 5 Year Change | -80.99% |
| Change since IPO | -90.74% |
Recent News & Updates
Recent updates
Estimating The Fair Value Of Medicure Inc. (CVE:MPH)
May 14
Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) Tunnel
Mar 08We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With Ease
Aug 28Medicure's (CVE:MPH) Earnings Are Weaker Than They Seem
Nov 30Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely
Jun 15Shareholder Returns
| MPH | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -8.3% | 10.1% | -0.5% |
| 1Y | -9.9% | -25.6% | 11.9% |
Return vs Industry: MPH exceeded the Canadian Biotechs industry which returned -25.6% over the past year.
Return vs Market: MPH underperformed the Canadian Market which returned 11.9% over the past year.
Price Volatility
| MPH volatility | |
|---|---|
| MPH Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MPH has not had significant price volatility in the past 3 months.
Volatility Over Time: MPH's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Albert Friesen | www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
| MPH fundamental statistics | |
|---|---|
| Market cap | CA$10.44m |
| Earnings (TTM) | -CA$1.16m |
| Revenue (TTM) | CA$21.76m |
0.5x
P/S Ratio-9.0x
P/E RatioIs MPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MPH income statement (TTM) | |
|---|---|
| Revenue | CA$21.76m |
| Cost of Revenue | CA$7.67m |
| Gross Profit | CA$14.09m |
| Other Expenses | CA$15.25m |
| Earnings | -CA$1.16m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 64.75% |
| Net Profit Margin | -5.34% |
| Debt/Equity Ratio | 0% |
How did MPH perform over the long term?
See historical performance and comparison